🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Yazan F. Madanat

Southwestern Medical Center

ORCID: 0000-0001-9573-2690

Also affiliated with Southwestern Medical Center, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 7 papers. Top paper: “A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents”.

A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents

Annals of Hematology(2023)10.1007/s00277-023-05552-4
N/A
0.726DataRank · unranked
23 citations

Rory M. Shallis, Elad Sharon, Silvia Park, Rahul Ramaswamy, Caroline E. Roe +18 more

A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia

Blood Neoplasia(2025)10.1016/j.bneo.2025.100126
N/A
0.330DataRank · unranked
8 citations

Gabriel N. Mannis, Yazan F. Madanat, Brian A. Jonas, Neil Dunavin, Gail J. Roboz +15 more

A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years

Cancer Research Communications(2025)10.1158/2767-9764.crc-25-0091
N/A
0.216DataRank · unranked
3 citations

Ronan Swords, Ying Huang, Shelley Orwick, Daelynn R. Buelow, Nicole Abbott +23 more

Navigating the dynamic landscape of lower-risk MDS: Advances and emerging insights

Blood Reviews(2025)10.1016/j.blre.2025.101301
N/A
0DataRank · unranked
2 citations

Yazan F. Madanat, Yasmin Abaza, Amer M. Zeidan, Alain Mina

Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants

Cancer Discovery(2024)10.1158/2159-8290.cd-24-0719
N/A
0DataRank · unranked
5 citations

Wenhuo Hu, Ashwin Kishtagari, Bo Shen, Xiang Gao, Caroline M. Blackman +19 more

Risk prediction for clonal cytopenia: multicenter real-world evidence

Blood(2024)10.1182/blood.2024024756
N/A
0DataRank · unranked
50 citations

Rami S. Komrokji, Najla Al‐Ali, Alexandra Regelson, Susan Geyer, Anand Patel +39 more

Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance

Cancer Discovery(2022)10.1158/2159-8290.cd-21-1661
N/A
0DataRank · unranked
19 citations

Yuxuan Liu, Lihu Gong, Mingyi Chen, Yazan F. Madanat, Yuannyu Zhang +23 more